To Study the Prevalence of Impaired Glucose Tolerance in Patients with Hepatitis C Virus Related Chronic Liver Disease

Kaur, Harpreet; Singh, Parminder; Pannu, Harminder Singh; Sood, Ajit; Jain, Narender Pal; Bhoday, Harpreet Singh

doi:10.7860/jcdr/2015/11444.5665

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as a high GA-LCV level, along with a high GA-M level, is largely accompanied by wide fluctuations in other parameters, at least in HD patients, it could also be a manifestation of diverse (not necessarily diabetes-related) types of organ/tissue damages and accompanying physiological dysregulation. This interpretation is compatible with the presence of impaired glucose tolerance in patients with various chronic diseases [31][32][33] as well as frail elderly 34 . Furthermore, it explains why dysglycemia in critically ill patients is associated with a high mortality and why strict glycemic control has a minimal effect on their prognosis 35 .…”

Section: Discussionsupporting

confidence: 75%

Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients

Nakazato

Sugiyama

Ohno

et al. 2020

Sci Rep

View full text Add to dashboard Cite

increased intraindividual variability in several biological parameters is associated with aspects of frailty and may reflect impaired physiological regulation. As frailty involves a cumulative decline in multiple physiological systems, we aimed to estimate the overall regulatory capacity by applying a principal component analysis to such variability. The variability of 20 blood-based parameters was evaluated as the log-transformed coefficient of variation (LCV) for one year's worth of data from 580 hemodialysis patients. All the LCVs were positively correlated with each other and shared common characteristics. In a principal component analysis of 19 LCVs, the first principal component (PC1) explained 27.7% of the total variance, and the PC1 score exhibited consistent correlations with diverse negative health indicators, including diabetes, hypoalbuminemia, hyponatremia, and relative hypocreatininemia. the relationship between the PC1 score and frailty was subsequently examined in a subset of the subjects. The PC1 score was associated with the prevalence of frailty and was an independent predictor for frailty (odds ratio per SD: 2.31, P = 0.01) using a multivariate logistic regression model, which showed good discrimination (c-statistic: 0.85). Therefore, the PC1 score represents principal information shared by biomarker variabilities and is a reasonable measure of homeostatic dysregulation and frailty. Studies on variability in blood pressure, plasma glucose levels, hemoglobin concentration, and other parameters have commonly reported associations with adverse outcomes 1-3. In our previous study examining patients receiving maintenance hemodialysis (HD), variability in many other blood-based laboratory parameters was also related to several adverse conditions, such as impaired mobility, hospital admission, increased mortality, and hypoalbuminemia 4. These conditions are in fact elements of frailty, and frailty is considered to be a state of functional decline in many physiological systems 5. Therefore, we speculated that the variability in laboratory parameters may reflect the dysfunction of corresponding regulatory systems and may also be a measure of frailty. Consistent with this idea, the variability of serum albumin concentrations increases with ageing, and this movement accelerates prior to death 6. Others have also suggested a link between physiological regulation and variability in other biological variables 7-10. However, the variability of a single parameter may not properly represent the dysregulation across multiple physiological systems in frailty 11. To develop a comprehensive measure of physiological dysregulation that is consistent with the concept of frailty, we applied a principal component analysis (PCA) to a set of variabilities in laboratory parameters. This procedure, performed on all study participants (n = 580), yielded principal component scores (PC scores) for

show abstract

Section: Discussionsupporting

confidence: 75%

Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients

Nakazato

Sugiyama

Ohno

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These results are consistent with literature [15][16][17]. The national prevalence of diabetes in Cameroon was 6.5% in 2015; this high frequency in patients with chronic C viral hepatitis is due to HCV-induced insulin resistance [21,22]. The median pre-therapeutic viral load was 1,183,000 IU/ mL and 58.2% of patients had a high viral load (≥ 800,000).…”

Section: Discussionsupporting

confidence: 89%

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Eloumou¹,

Mouto²,

Bekolo³

et al. 2018

Clin Infect Immun

View full text Add to dashboard Cite

Background: There has been a revolution in the treatment of hepatitis C virus (HCV) infection since the introduction of new direct-acting antivirals agents (DAAs) in 2014. About 95% of the patients have a sustained virological response (SVR) after 12 weeks with DAAs. The aim of this study was to evaluate the SVR after 12 weeks of treatment with the combination of sofosbuvir (SOF)/ledipasvir (LDV) +/-ribavirin (RBV) among a cohort of Cameroonian HCV carriers.Methods: This was a cross-sectional study in HCV treatment centers in Cameroon health facilities in Yaounde and Douala. It focused on patients with chronic HCV of genotypes 1 and 4 treated with the SOF/ LDV +/-RBV combination for 12 weeks. The virological response after 4 and 12 weeks of treatment was determined. SVR indicating recovery was determined 12 weeks after the end of treatment (SVR12). Results:A total of 111 patients with chronic HCV were included. There was female predominance with a proportion of 58.6%. The average age of the patients was 58.8 ± 8.2 years. Genotype 1 was the most frequent with 68.5% of the cases. The SVR was 93.7% (95% CI (87.4% -97.4%)) regardless of protocol and genotype. HCV infection without cirrhosis was associated with good SVR (aOR = 0.1, 95 CI (0.1 -0.9), P = 0.02). The most common clinical adverse reaction was asthenia with 12.5% (n = 10). Conclusions:The SVR12 in Cameroonian patient infected with HCV genotypes 1 and 4 treated with the combination SOF/LDV +/-RBV was 93.7%. Cirrhosis is a factor of poor response.

show abstract

“…In our study, we observed 27.3% of HCV patients with impaired fasting glucose at baseline, whereas 11.3% of HCV patients developed IFG during 24 weeks of anti-viral therapy. Previous studies also suggested that HCV patients were more susceptible to developing insulin resistance (21) and impaired glucose tolerance (22). Therefore, our results reinforced the evidence that chronic HCV infection and diabetes were inter-related.…”

Section: Discussionmentioning

confidence: 99%

Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy

Sun

Wang

et al. 2016

Hepat Mon

View full text Add to dashboard Cite

BackgroundRecent studies have indicated that abnormal glucose levels and diabetes are negatively associated with the prognosis of patients with chronic hepatitis C virus (HCV) infection. The genetic polymorphism of the promoter region -1260 of a gene encoding the enzyme 1-alpha-hydroxylase (CYP27B1-1260) has been shown to have an impact on the signaling pathways involved in insulin secretion.ObjectivesThe aim is to investigate the effect of CYP27B1-1260 polymorphism on the fasting plasma glucose (FPG) levels in patients with chronic HCV undergoing antiviral therapy.Patients and MethodsA total of 461 patients with chronic HCV infection and 300 volunteers without HCV infection were enrolled in an observational cohort study in the China-Japan Union hospital of Jilin University and the Second Hospital of Daqing, Changchun, Jilin Province. Both groups were further divided into normal and abnormal FPG subgroups. The frequencies of the three CYP27B1-1260 genotypes (AA, AC, and CC) were determined in each subgroup. FPG levels were monitored at baseline in HCV and control participants, and both during and after antiviral therapy in HCV infected patients. The frequency of each genotype was determined. Logistic regression analysis was performed to evaluate the risk factors associated with abnormal FPG levels in HCV infected patients undergoing antiviral therapy.ResultsIn HCV infected patients with abnormal FPG levels, the frequency of the genotype CC was significantly higher than that in patients with normal FPG levels (19% vs. 7%, P < 0.001). In contrast, in the control participants, the CC genotype was not significantly different between FPG groups. At baseline, the CC genotype was associate with four times more risk of IFG after adjusting for multiple variables (OR: 4.11; 95%CI: 1.98 - 8.52, P = 0.0001). During 24 weeks of anti-HCV treatment, 38 HCV participants developed newly-diagnosed impaired fasting glucose. The CC genotype markedly increased the risk for newly developed IFG (OR: 26.54; 95%CI: 7.80 - 90.32, P < 0.0001). Other risk factors included age and body mass index.ConclusionsCYP27B1-1260 polymorphism is associated with abnormal glucose metabolism in HCV infected patients. HCV infected individuals with CYP27B1-1260 genotype CC appeared to have an increased risk of developing abnormal FPG levels.

show abstract

To Study the Prevalence of Impaired Glucose Tolerance in Patients with Hepatitis C Virus Related Chronic Liver Disease

Cited by 5 publications

References 27 publications

Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients

Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Genetic Polymorphism of CYP27B1-1260 as Associated With Impaired Fasting Glucose in Patients With Chronic Hepatitis C Undergoing Antiviral Therapy

Contact Info

Product

Resources

About